MCID: ANR038
MIFTS: 27

Anorexia Nervosa 1

Categories: Genetic diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Anorexia Nervosa 1

MalaCards integrated aliases for Anorexia Nervosa 1:

Name: Anorexia Nervosa 1 54 29
Anorexia Nervosa 54 69
Anorexia Nervosa, Susceptibility to, 1 13

Classifications:



External Ids:

OMIM 54 606788

Summaries for Anorexia Nervosa 1

OMIM : 54
Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788)

MalaCards based summary : Anorexia Nervosa 1, also known as anorexia nervosa, is related to anorexia nervosa and eating disorder. An important gene associated with Anorexia Nervosa 1 is HTR2A (5-Hydroxytryptamine Receptor 2A). The drugs Aripiprazole and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include bone and brain.

Related Diseases for Anorexia Nervosa 1

Diseases in the Anorexia Nervosa family:

Anorexia Nervosa 1

Diseases related to Anorexia Nervosa 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
id Related Disease Score Top Affiliating Genes
1 anorexia nervosa 12.8
2 eating disorder 11.6
3 body dysmorphic disorder 11.4
4 pili torti 11.3
5 bulimia nervosa 10.7
6 obesity 10.5
7 amenorrhea 10.4
8 gastric dilatation 10.3
9 hypophosphatemia 10.3
10 obsessive-compulsive disorder 10.2
11 personality disorder 10.1
12 cerebritis 10.1
13 superior mesenteric artery syndrome 10.1
14 gonadal dysgenesis 10.1
15 central pontine myelinolysis 10.1
16 alexithymia 10.1
17 pancreatitis 10.1
18 insulin-like growth factor i 10.1
19 enteropathica 10.0
20 cerebral atrophy 10.0
21 nephrocalcinosis 10.0
22 anxiety disorder 10.0
23 acrodermatitis enteropathica 10.0
24 acrodermatitis 10.0
25 hypoglycemic coma 10.0
26 obsessive-compulsive personality disorder 10.0
27 pellagra 10.0
28 osteoporosis 10.0
29 morbid obesity 10.0
30 thyroiditis 10.0
31 hypoglycemia 9.9
32 schizophrenia 9.9
33 pancytopenia 9.9
34 conversion disorder 9.9
35 kwashiorkor 9.9
36 addison's disease 9.9
37 achalasia 9.9
38 trichotillomania 9.9
39 pericardial effusion 9.9
40 scurvy 9.9
41 cushing's syndrome 9.9
42 delusional disorder 9.9
43 asperger syndrome 9.8
44 congenital adrenal hyperplasia 9.8
45 wernicke-korsakoff syndrome 9.8
46 gender identity disorder 9.8
47 cardiomyopathy 9.8
48 borderline personality disorder 9.8
49 graves' disease 9.8
50 pneumothorax 9.8

Graphical network of the top 20 diseases related to Anorexia Nervosa 1:



Diseases related to Anorexia Nervosa 1

Symptoms & Phenotypes for Anorexia Nervosa 1

Clinical features from OMIM:

606788

Drugs & Therapeutics for Anorexia Nervosa 1

Drugs for Anorexia Nervosa 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
2
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
7
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
8 Raclopride Investigational Phase 4 84225-95-6
9 Antipsychotic Agents Phase 4,Phase 3,Phase 2
10 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
11 Psychotropic Drugs Phase 4,Phase 3,Phase 2
12 Tranquilizing Agents Phase 4,Phase 3,Phase 2
13 Antiemetics Phase 4,Phase 3,Phase 2
14 Autonomic Agents Phase 4,Phase 3,Phase 2
15 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
19
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
20 Serotonin Agents Phase 4,Phase 3,Phase 2
21 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
22 Dopamine Agents Phase 4
23 Dopamine Antagonists Phase 4
24 Serotonin Antagonists Phase 4
25 Antidepressive Agents Phase 4
26 Antidepressive Agents, Second-Generation Phase 4
27 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Adrenergic Agents Phase 4
30 Central Nervous System Stimulants Phase 4
31 Dopamine Uptake Inhibitors Phase 4
32
Teriparatide Approved, Investigational Phase 3 52232-67-4 16133850
33
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078 2978
34
Etidronic acid Approved Phase 2, Phase 3 7414-83-7, 2809-21-4 3305
35
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
36
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 6013
37
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3, Phase 1 50-28-2 5757
38
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
39
Medroxyprogesterone acetate Approved, Investigational Phase 2, Phase 3,Phase 1 71-58-9
40
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
41
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
42
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7, 17489-40-6 13109
43 Racepinephrine Approved Phase 2, Phase 3
44
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
45
Denosumab Approved Phase 3,Early Phase 1 615258-40-7
46
Dehydroepiandrosterone Approved, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
47 tannic acid Approved, Nutraceutical Phase 3
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
49 Bone Density Conservation Agents Phase 3,Phase 2,Early Phase 1
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 100)

id Name Status NCT ID Phase Drugs
1 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
2 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
3 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
4 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
5 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
6 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
7 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
8 Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
9 Bone Loss in Women With Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
10 Effects of Anorexia Nervosa on Bone Mass in Adolescents Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
11 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
12 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
13 The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa Completed NCT02004288 Phase 2, Phase 3
14 Hormonal Therapy for Teens With Anorexia Nervosa Completed NCT01343771 Phase 3 DHEA (Prasterone) + ERT (Aviane)
15 Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
16 Effects of Anorexia Nervosa on Peak Bone Mass Recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
17 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
18 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Recruiting NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
19 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3 Olanzapine
20 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
21 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
22 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
23 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
24 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
25 Olanzapine in the Treatment of Patients With Anorexia Nervosa Completed NCT00260962 Phase 2 Olanzapine
26 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
27 Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Completed NCT00183586 Phase 2
28 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
29 A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
30 Therapeutic Effects of Neurofeedback in Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
31 Treatment for Young Adults With Anorexia Nervosa Completed NCT01190423 Phase 1, Phase 2
32 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01678014 Phase 1
33 Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
34 Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01476540 Phase 1
35 Funen Anorexia Nervosa Study - Retrospective Cohort Study and 10 Year Follow-up Study Unknown status NCT00267228 Phase 1
36 Yoga in Treatment of Eating Disorders Unknown status NCT00870753 Phase 1
37 Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa Completed NCT00601822 Phase 1
38 Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa Completed NCT00149786 Phase 1
39 Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1
40 Estradiol and Fear Extinction in Anorexia Nervosa (AN) Recruiting NCT02792153 Phase 1 Estradiol
41 Reward Systems and Food Avoidance in Eating Disorders Recruiting NCT02795455 Phase 1
42 Efficacity of Cognitive Remediation Treatment Compared to a Controlled Group in Young Patient With Anorexia Nervosa Recruiting NCT02400541 Phase 1
43 Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters Unknown status NCT00493519
44 Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients Unknown status NCT02164487
45 Self-Help And Recovery Guide in Eating Disorders Unknown status NCT02336841 Early Phase 1
46 Drug Transport in Patients With Anorexia Nervosa Unknown status NCT00176150
47 New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment Unknown status NCT02382497
48 Trial of Quetiapine in Anorexia Nervosa Unknown status NCT00518973 Quetiapine
49 Bone Loss in Patients With Anorexia Nervosa Unknown status NCT01907464
50 The Embodied Cognition: Exploratory Study of Automatic and Controlled Processes in Anorexia Nervosa. Completed NCT02538796

Search NIH Clinical Center for Anorexia Nervosa 1

Genetic Tests for Anorexia Nervosa 1

Genetic tests related to Anorexia Nervosa 1:

id Genetic test Affiliating Genes
1 Anorexia Nervosa 1 29

Anatomical Context for Anorexia Nervosa 1

MalaCards organs/tissues related to Anorexia Nervosa 1:

39
Bone, Brain

Publications for Anorexia Nervosa 1

Variations for Anorexia Nervosa 1

Expression for Anorexia Nervosa 1

Search GEO for disease gene expression data for Anorexia Nervosa 1.

Pathways for Anorexia Nervosa 1

GO Terms for Anorexia Nervosa 1

Sources for Anorexia Nervosa 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....